[go: up one dir, main page]

WO2004041296A3 - Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides - Google Patents

Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides Download PDF

Info

Publication number
WO2004041296A3
WO2004041296A3 PCT/DK2003/000752 DK0300752W WO2004041296A3 WO 2004041296 A3 WO2004041296 A3 WO 2004041296A3 DK 0300752 W DK0300752 W DK 0300752W WO 2004041296 A3 WO2004041296 A3 WO 2004041296A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
polypeptides
pharmaceutical composition
tissue factor
factor antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2003/000752
Other languages
French (fr)
Other versions
WO2004041296A2 (en
Inventor
Lars Christian Petersen
Jakob Michael Back
Christian Meyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to AU2003275948A priority Critical patent/AU2003275948A1/en
Publication of WO2004041296A2 publication Critical patent/WO2004041296A2/en
Publication of WO2004041296A3 publication Critical patent/WO2004041296A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a composition comprising a TF antagonist and protein C or a protein C-related polypeptide, and the use thereof for treating Thrombotic or Coagulopathic relatedl diseases, Respiratory diseases and Inflammatory diseases.
PCT/DK2003/000752 2002-11-06 2003-11-04 Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides Ceased WO2004041296A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003275948A AU2003275948A1 (en) 2002-11-06 2003-11-04 Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200201709 2002-11-06
DKPA200201709 2002-11-06

Publications (2)

Publication Number Publication Date
WO2004041296A2 WO2004041296A2 (en) 2004-05-21
WO2004041296A3 true WO2004041296A3 (en) 2004-07-29

Family

ID=32309251

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2003/000752 Ceased WO2004041296A2 (en) 2002-11-06 2003-11-04 Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides

Country Status (2)

Country Link
AU (1) AU2003275948A1 (en)
WO (1) WO2004041296A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12246025B2 (en) 2018-03-21 2025-03-11 Genmab A/S Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
US12453781B2 (en) 2018-10-30 2025-10-28 Genmab A/S Methods of treating cancer with a combination of an anti-VEGF antibody and an anti-tissue factor antibody-drug conjugate

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064870A2 (en) * 2003-01-22 2004-08-05 Novo Nordisk A/S Radiolabelled tissue factor binding agent and the use thereof
UA109633C2 (en) 2008-12-09 2015-09-25 HUMAN ANTIBODY AGAINST TISSUE FACTOR
SMT201700547T1 (en) 2010-06-15 2018-01-11 Genmab As Human antibody drug conjugates against tissue factor
CN104394883B (en) 2012-07-04 2017-05-31 悉尼大学 Treatment of Inflammatory Skin Conditions
EP3137102B1 (en) 2014-04-16 2021-07-14 ZZ Biotech LLC Apc for use in the treatment of abnormal cutaneous scarring
US20170035862A1 (en) 2014-04-16 2017-02-09 Zz Biotech Llc Use of APC analogue for wound healing
UA130009C2 (en) 2018-05-07 2025-10-15 Генмаб А/С Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001059084A1 (en) * 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001059084A1 (en) * 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] June 1998 (1998-06-01), HOLST J ET AL: "Local application of recombinant active-site inhibited human clotting factor VIIa reduces thrombus weight and improves patency in a rabbit venous thrombosis model.", XP002281243, Database accession no. NLM9659887 *
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY: THE OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR VASCULAR SURGERY. ENGLAND JUN 1998, vol. 15, no. 6, June 1998 (1998-06-01), pages 515 - 520, ISSN: 1078-5884 *
JOYCE C.Y. CHAN ET AL: "Combined factor VII/protein C deficiency results in intrauterine coagulopathy in mice", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 105, no. 7, April 2000 (2000-04-01), pages 897 - 903, XP002281241 *
LEONARD PRESTA ET AL: "Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeuctic", THROMB HACMOST, vol. 85, 2001, pages 379 - 389, XP002281242 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12246025B2 (en) 2018-03-21 2025-03-11 Genmab A/S Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
US12453781B2 (en) 2018-10-30 2025-10-28 Genmab A/S Methods of treating cancer with a combination of an anti-VEGF antibody and an anti-tissue factor antibody-drug conjugate

Also Published As

Publication number Publication date
AU2003275948A8 (en) 2004-06-07
AU2003275948A1 (en) 2004-06-07
WO2004041296A2 (en) 2004-05-21

Similar Documents

Publication Publication Date Title
IL161016A (en) Polypeptides capable of binding to ang-2
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
AU2003228809A1 (en) Kinase anchor protein muteins, peptides thereof, and related methods
WO2005056585A3 (en) Sars coronavirus s proteins and uses thereof
WO2005000877A3 (en) Novel melanocortin receptor templates, peptides, and use thereof
WO2004041296A3 (en) Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
WO2006056987A3 (en) Leptin antagonists
WO2003087138A3 (en) Methods for identifying polypeptide factors interacting with rna
WO2005059131A3 (en) Protein binding miniature proteins and uses thereof
WO2002068476A3 (en) Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
AU2002365269A8 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
EP1808179A3 (en) Use of HSP20 for promoting wound healing and/or reducing scar formation
EP1908778A4 (en) Exendin 4 polypeptide fragments and use thereof
WO2005086825A3 (en) Methods and compositions for treatment of diseases associated with aberrant microsatellite expansion
WO2005097826A3 (en) Prokineticin 2beta peptide and its use
IL193310A0 (en) Antibody directed against a polypeptide that interacts with parkin and pharmaceutical compositions comprising the same
IL172269A0 (en) Improved recombinant human interferon-beta-ib polypeptides
WO2003074656A3 (en) Rank-ligand-induced sodium/proton antiporter polypeptides
WO2003100001A3 (en) Claudin polypeptides, polynucleotides, and methods of making and use thereof
WO1999014322A3 (en) Allelic variant of human stat3
WO2006103354A3 (en) Dermatological and/or cosmetic composition containing proteins of the sirt family
WO2004003133A3 (en) Pain signaling molecules
AU2002342858A1 (en) Human high-affinity antibody fragments for essential proteins of the hepatitis-c virus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP